Ultragenyx Reports Third Quarter 2020 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St futures rebound as oil retreats, investors weigh US-Iran tensions
- Oil prices fall as markets weigh impact of US strikes on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Ultragenyx Pharma (RARE) PT Raised to $116 at Cowen
October 28, 2020 6:59 AM EDTCowen analyst Yaron Werber raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $116.00 (from $90.00) while maintaining an Outperform rating.
The analyst commented, "RARE reported Q3:20 earnings with OpEx of $132M v our $128M estimates & steady growth in sales of Crysvita & Dojolvi.... More
Ultragenyx Pharma (RARE) Tops Q3 EPS by 14c, Revenues Beat
October 27, 2020 4:45 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.13), $0.14 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $81.5 million versus the consensus estimate of $53.89 million.
Third quarter 2020 total revenue of $81.5 million and Crysvita revenue of $37.3 millionIncreased lower end of... More